Cefrin

Indonesia • Dexa Medica

Indication

For infection treatment, whether before the causative organism is known or infections caused by bacterial organisms sensitive to cefpirome:

  • Lower respiratory tract infections (bronchopneumonia, lobar pneumonia)
  • Complicated upper urinary tract infections (pyelonephritis)
  • Complicated lower urinary tract infections
  • Skin and soft tissue infections (cellulitis, skin abscess and infected wound)
  • Infections in neutropenic patients
  • Bacteremia / septicemia
  • Severe infections

Composition

Cefpirome 1 g

Package

1 vial of 1 g

Dosage Forms

Powder for Injection

ATC Classification

J01D

Warning

Alcohol
Consult Your Doctor
Safety of this item for use with alcohol has not been established. Please consult your doctor.
Machinery
Consult Your Doctor
Safety of this item for use while operating heavy machinery has not been established. Please consult your doctor.
Pregnancy
Not Recommended
This item is not safe for use during pregnancy.
Lactation
Not Recommended
This item is not safe for use during lactation.

Dosage

0 to 12 Years Old

Clinical data for children <12 years of age is insufficient. Therefore, cefpirome should not be used for this age group.

18 Years Old and Above

The following dosages are recommended for moderate to severe infections in patients with normal renal function:

Complicated upper and lower urinary tract infections

  • Unit dose: 1 g
  • Dosage intervals: 12 hours
  • Total daily dose: 2 g

Skin and soft tissue infections

  • Unit dose: 1 g
  • Dosage intervals: 12 hours
  • Total daily dose: 2 g

Lower respiratory tract infections

  • Unit dose: 1 to 2 g
  • Dosage intervals: 12 hours
  • Total daily dose: 2 to 4 g

Bacteremia/septicemia

  • Unit dose: 2 g
  • Dosage intervals: 12 hours
  • Total daily dose: 4 g

Infections in neutropenic patients

  • Unit dose: 2 g
  • Dosage intervals: 12 hours
  • Total daily dose: 4 g

Severe infections

  • Unit dose: 2 g
  • Dosage intervals: 12 hours
  • Total daily dose: 4 g

For urinary tract and skin and soft tissue infections, the unit dose may be increased to 2 g in very severe cases.

65 Years Old and Above

No adjustment is required unless renal impairment is present.

Patients with Impaired Renal Function

Cefpirome is excreted principally by the kidney. The dose must therefore be reduced in patients with impaired renal function to compensate for the slower excretion. The recommended dosages are:

CrCl 20-50 ml/minute

  • Initial dose 1 g, maintenance dose 0.5 g twice daily
  • Initial dose 2 g, maintenance dose 1 g twice daily

CrCl 5-20 ml/minute

  • Initial dose 1 g, maintenance dose 0.5 g once daily
  • Initial dose 2 g, maintenance dose 1 g once daily

CrCl ˂5 ml/minute (in hemodyalysis patients)

  • Initial dose 1 g, maintenance dose 0.5 g once daily ± 0.25 g immediately after dialysis
  • Initial dose 2 g, maintenance dose 1 g once daily ± 0.5 g immediately after dialysis